Free Trial

SCYNEXIS (SCYX) Competitors

SCYNEXIS logo
$0.71 +0.00 (+0.37%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$0.71 +0.00 (+0.37%)
As of 08:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SCYX vs. BHST, GNLX, TARA, ATOS, HURA, PROC, CCCC, ANIX, MIST, and MCRB

Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include BioHarvest Sciences (BHST), Genelux (GNLX), Protara Therapeutics (TARA), Atossa Genetics (ATOS), TuHURA Biosciences (HURA), Procaps Group (PROC), C4 Therapeutics (CCCC), Anixa Biosciences (ANIX), Milestone Pharmaceuticals (MIST), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry.

SCYNEXIS vs. Its Competitors

SCYNEXIS (NASDAQ:SCYX) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

In the previous week, BioHarvest Sciences had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 1 mentions for BioHarvest Sciences and 0 mentions for SCYNEXIS. BioHarvest Sciences' average media sentiment score of 0.78 beat SCYNEXIS's score of 0.00 indicating that BioHarvest Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
SCYNEXIS Neutral
BioHarvest Sciences Positive

BioHarvest Sciences has a net margin of -31.30% compared to SCYNEXIS's net margin of -1,030.04%. SCYNEXIS's return on equity of -53.47% beat BioHarvest Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
SCYNEXIS-1,030.04% -53.47% -32.86%
BioHarvest Sciences -31.30%-307.04%-33.21%

54.4% of SCYNEXIS shares are owned by institutional investors. 4.9% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

SCYNEXIS has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, BioHarvest Sciences has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.

BioHarvest Sciences has a consensus target price of $13.67, indicating a potential upside of 91.41%. Given BioHarvest Sciences' stronger consensus rating and higher possible upside, analysts plainly believe BioHarvest Sciences is more favorable than SCYNEXIS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SCYNEXIS
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
BioHarvest Sciences
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

BioHarvest Sciences has higher revenue and earnings than SCYNEXIS. BioHarvest Sciences is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SCYNEXIS$3.75M7.39-$21.29M-$0.56-1.27
BioHarvest Sciences$25.19M4.65-$12.91M-$0.50-14.28

Summary

BioHarvest Sciences beats SCYNEXIS on 9 of the 16 factors compared between the two stocks.

Get SCYNEXIS News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCYX vs. The Competition

MetricSCYNEXISMED IndustryMedical SectorNASDAQ Exchange
Market Cap$27.62M$2.68B$5.50B$8.94B
Dividend YieldN/A1.79%5.25%4.04%
P/E Ratio-1.278.9826.9720.11
Price / Sales7.39714.59426.02119.76
Price / CashN/A159.8036.8257.86
Price / Book0.494.517.985.56
Net Income-$21.29M$31.26M$3.16B$248.40M
7 Day Performance-1.35%3.57%2.36%4.67%
1 Month Performance-17.40%1.28%2.15%6.64%
1 Year Performance-63.76%1.08%33.78%21.31%

SCYNEXIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCYX
SCYNEXIS
0.258 of 5 stars
$0.71
+0.4%
N/A-63.0%$27.62M$3.75M-1.2760
BHST
BioHarvest Sciences
N/A$7.06
+2.3%
$13.67
+93.6%
N/A$113.33M$27.70M-14.12N/AHigh Trading Volume
GNLX
Genelux
1.9758 of 5 stars
$2.90
-2.7%
$17.75
+512.1%
+62.6%$112.45MN/A-3.3010
TARA
Protara Therapeutics
1.6728 of 5 stars
$2.80
-3.1%
$20.50
+632.1%
+45.0%$111.50MN/A-1.6330
ATOS
Atossa Genetics
1.5831 of 5 stars
$0.85
-0.4%
$6.17
+629.1%
-26.3%$109.68MN/A-4.038
HURA
TuHURA Biosciences
1.2372 of 5 stars
$2.40
-3.2%
$12.67
+427.8%
N/A$108.33MN/A0.00N/A
PROC
Procaps Group
N/A$0.95
-40.3%
N/A-62.0%$107.18M$409.92M0.004,900Gap Down
High Trading Volume
CCCC
C4 Therapeutics
1.444 of 5 stars
$1.52
+2.7%
$12.00
+689.5%
-61.4%$105.09M$35.58M-1.03150
ANIX
Anixa Biosciences
2.6545 of 5 stars
$3.21
-0.6%
$9.00
+180.4%
+38.3%$104.04M$210K-8.455News Coverage
MIST
Milestone Pharmaceuticals
3.2009 of 5 stars
$2.17
+11.9%
$7.00
+222.6%
+65.4%$103.72M$1M-2.7830News Coverage
High Trading Volume
MCRB
Seres Therapeutics
3.5429 of 5 stars
$10.85
-8.6%
$73.67
+579.0%
-40.4%$103.65M$126.32M-2.36330Positive News

Related Companies and Tools


This page (NASDAQ:SCYX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners